FEXI 12

Duración

04/10/2017 - 31/12/2018

Coordinador

Joaquim Gascon

Financiadores

DNDi

Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study

The general objective of this clinical trial is to determine the efficacy and safety of alternative dosing regimens of FEXI in reducing and clearing T. cruzi parasitemia in adult individuals with the chronic indeterminate Chagas Disease, in comparison to historical placebo control.

This is  a double-blind, randomized, prospective, comparative, pharmacokineticpharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control. The trial will be conducted in 5 different sites in Spain. The trial will be sufficiently powered to compare the efficacy and safety of each of the dosing regimens of FEXI with historical placebo control. Efficacy and safety will be monitored by an external independent Data Monitoring Committee (DMC) on an ongoing basis. The committee is to include cardiac and liver safety experts, as well as Chagas Disease clinical expertise.

The total duration of patient trial participation will be approximately 14 months.